In the past month, FibroBiologics, Inc. (NASDAQ: FBLG) has disclosed the advancement of its fibroblast therapy platform into additional indications, including: On March 2, 2026, the company announced ...
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
HOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development ...
HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
A new study reviews how cancer-associated fibroblasts (CAFs) influence lymph node metastasis. Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer ...
On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...
Age-related changes in the fibroblasts, cells that create the skin's structure, contribute to the development of aggressive, treatment-resistant melanoma in males, according to research in mice by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results